Notably, compared with the original sBBI and commercial Anti-PD-L1 inhibitors, the designed sBBI&PDP showed stronger antitumor efficacy in an orthotopic homograft mice model of HCC and a PDX HCC model in hu-PBMC-NSG mice. This evidence concerns the gene PDP1 and hepatocellular carcinoma.